Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:03:10.278Z.
Calculation as of: 2026-10-06T17:03:10.278Z.
Quote observation: 2026-10-06T17:00:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c3dbe71a0fe55431d15913f230b0583615770e6f1642b2e59d58eeac51dced7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$2.37M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.54M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.54M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.31M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.15M
EV/EBIT Ratio
N/A
TTM Avg
26760113783.26x
3Y Avg
32032508565.60x
5Y Avg
32032508565.60x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | $2.45M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.38M | N/A | N/A | N/A | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.56M | N/A | N/A | N/A | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.37M | N/A | N/A | N/A | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.54M | N/A | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | N/A | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.61M | N/A | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.15M | N/A | 26760113783.26x | 32032508565.60x | 32032508565.60x |
| iSpecimen Inc. (ISPC)vs › | $2.67M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
